SCHEMBL23964281

SCHEMBL23964281

FC(F)(F)c1ccc2cc(CN3CCN(c4ccncc4)CC3)[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.56
DRD4 P21917 9/20 0.51
DRD2 P14416 7/20 0.51
DRD3 P35462 7/20 0.51
DRD1 P21728 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
KDM4E B2RXH2 2/20 0.44
POLB P06746 1/20 0.44
HTR2A P28223 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
GRM2 Q14416 1/20 0.43
RPS6KB1 P23443 1/20 0.42
DGAT1 O75907 1/20 0.42
SOAT1 P35610 1/20 0.42
KCNH2 Q12809 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040795 1.00 SLC2A1 (0.56) SLC2A1DRD4DRD2DRD3DRD1
SCHEMBL23964157 0.91 SLC2A1 (0.54) SLC2A1DRD4DRD2DRD3KDM4E
SCHEMBL30041336 0.82 DRD4 (0.55) DRD4DRD2DRD3DRD1SIGMAR1
SCHEMBL30042123 0.82 DRD2 (0.54) SLC2A1DRD4DRD2DRD3HTR1A
SCHEMBL23932491 0.82 DRD4 (0.55) DRD4DRD2DRD3DRD1SIGMAR1
SCHEMBL23964180 0.82 DRD2 (0.54) SLC2A1DRD4DRD2DRD3HTR1A
SCHEMBL23964138 0.81 SLC2A1 (0.62) SLC2A1DRD4HTR2ARPS6KB1DGAT1
SCHEMBL23964200 0.81 HRH4 (0.63) DRD4DRD2DRD3HTR1AADRA2A
SCHEMBL23964189 0.81 DRD4 (0.51) SLC2A1DRD4DRD2DRD3POLB
SCHEMBL30041451 0.81 HRH4 (0.63) DRD4DRD2DRD3HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 SLC2A1 3090/4885DRD4 4746/4885DRD2 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.